Health
Exploring Ongoing Trials With 177Lu-PSMA-617 in Prostate Cancer – Targeted Oncology
Arun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.
Arun Azad, MBBS, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne, and chair of the ANZUP Cancer Trials Group Translational, discusses ongoing studies of lutetium-177-PSMA (177Lu-PSMA-617) radionuclide in patients with prostate cancer.
Theres the UpFrontPSMA trial (NCT04343885), a randomized phase 2 study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel alone in patients with metastatic hormone-naïve prostate cancer that is recruiting right now….
-
Noosa News11 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
General23 hours agoAn open letter to pro-Palestinian protesters
-
Business13 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
Noosa News13 hours agoBrisbane news live: 80,000 green bins rolled out | Residents told to prepare for ‘violent’ summer storms | Council declares water safe for swimming despite dead fish